Juno Therapeutics (JUNO) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. LDOS
8. HUM
9. CSCO
10. KTOS

Go back to Juno Therapeutics (JUNO) Misses Q2 EPS by 4c

Juno Therapeutics Reports Second Quarter 2015 Financial Results

August 12, 2015 4:05 PM EDT

-- JCAR015 IND FDA clearance allows initiation of Juno's first pivotal trial -- -- Transformative partnership with Celgene -- -- Substantial R&D progress with key acquisition integrations on track -- -- Conference call to be held today at 5:00pm Eastern Time

SEATTLE, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the second... More

Juno Therapeutics Reports Second Quarter 2015 Financial Results

August 12, 2015 4:05 PM EDT

-- JCAR015 IND FDA clearance allows initiation of Juno's first pivotal trial -- -- Transformative partnership with Celgene -- -- Substantial R&D progress with key acquisition integrations on track -- -- Conference call to be held today at 5:00pm Eastern Time

SEATTLE, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the second... More